GLUE - NASDAQ
Monte Rosa Therapeutics, Inc.
$17.39
-2.0%Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
At a Glance
Live Snapshotglue
Total Investments
Last Annual Value
247.22M
3-Year CAGR
6%
5-Year CAGR
192%
10-Year CAGR
%
Monte Rosa Therapeutics, Inc. Competitors Analysis of Total Investments
| Company | Total Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Monte Rosa Therapeutics, Inc. NASDAQ:GLUE | 247.22M | 33.3% | 115.3% | N/A | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 6.75M | -0.1% | 0.3% | 31.3% | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 267.28M | N/A | N/A | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 543.33M | -26.8% | -0.7% | N/A | |
 Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 270.48M | 51.4% | 18.6% | N/A | |
 Geron Corporation NASDAQ:GERN | 321.65M | 1.6% | 12.6% | 10.7% | |
 Theravance Biopharma, Inc. NASDAQ:TBPH | 161.90M | 37.1% | 1.3% | -4.2% | |
 Arvinas, Inc. NASDAQ:ARVN | 542.50M | -17.0% | -17.2% | 33.4% | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 244.03M | 21.6% | N/A | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 372.69M | -5.2% | 4.9% | N/A |
Monte Rosa Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your GLUE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.